Search
mRNA-1010
go.drugbank.com/drugs/DB22484Approved[L64058] The FDA approved mFLUSIVA on August 5, 2026 for active immunization against influenza in adults 50 years of age and older, making it the first mRNA-based influenza vaccine approved in the United … benefit to be confirmed in a postmarketing trial.
Midostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalIt was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Synonyms: 4'-N-benzoylstaurosporineTechnetium Tc-99m medronate
go.drugbank.com/drugs/DB09138ApprovedInvestigationalLike other bisphosphonates used in the treatment of osteoporosis, medronic acid binds to the hydroxyapatite crystals within bone, and in this way localizes the drug to bone for delineation of areas of … Technetium (99mTc) medronic acid is a pharmaceutical product used in nuclear medicine imaging. It is composed of a technetium ion complexed with medronic acid, a type of bisphosphonate.
Categories: Compounds used in a research, industrial, or household settingSynonyms: AN-MDPMogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigational[L4168] It was approved for the same indications in Canada in June 2022. … [L4170] On August 8 2018, the U.S.
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalIt was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].
Glatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively.
Products: Copaxone 20 mg/ml Injektionslösung in einer Fertigspritze, Copaxone 40 mg/ml Injektionslösung in einer FertigspritzeVaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigational[A32053] It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. … Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore.
Technetium Tc-99m nofetumomab merpentan
go.drugbank.com/drugs/DB09336ApprovedWithdrawnIt was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.
Dihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedAlpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049] … These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine.